Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06307795 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Locally Advanced or Metastatic Solid Tumors, sponsored by Avistone Biotechnology Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
- 10
- Study locations
NCT06307795 is a Phase 1 study of Locally Advanced or Metastatic Solid Tumors that is actively recruiting participants, run by Avistone Biotechnology Co.. The registered enrollment target is 63 participants, below the 286-participant average among 5 other Locally Advanced or Metastatic Solid Tumors trials with a reported enrollment target (78% lower). The trial reports 10 study locations across 10 states.
The verdict
NCT06307795, a Phase 1 study of Locally Advanced or Metastatic Solid Tumors, is actively recruiting participants, sponsored by Avistone Biotechnology Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.
Conditions Studied
Interventions
- DRUG ANS014004
Study Locations (10)
California
- University of California, San Diego - San Diego
Colorado
- Sarah Cannon Research Institute - Denver
Florida
- Advent Health - Orlando
Michigan
- Henry Ford Health Cancer - Detroit
New York
- NYU Langone Health - New York
Texas
- The University of Texas - MD Anderson Cancer Center - Houston
Virginia
- NEXT Oncology, Virginia - Fairfax
Washington
- Swedish Cancer Institute - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2024-06-24 |
| Est. Completion | 2027-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06307795
The ClinicalTrials.gov registry entry for NCT06307795 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 286-participant average among 5 other Locally Advanced or Metastatic Solid Tumors trials with a reported enrollment target (78% lower). The listed sponsor is Avistone Biotechnology Co., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced or Metastatic Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which ANS014004 is the first listed.
NCT06307795 reports 10 study locations spanning 10 distinct geographic areas - top geographies include California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT06307795 about?
NCT06307795 is a clinical study titled "A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors". This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.
What is the current status of trial NCT06307795?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2024-06-24. Estimated completion is 2027-10.
What conditions does trial NCT06307795 study?
This clinical trial studies the following conditions: Locally Advanced or Metastatic Solid Tumors.
What interventions are being tested in trial NCT06307795?
The interventions under investigation include: ANS014004 (DRUG).
Who is sponsoring clinical trial NCT06307795?
This trial is sponsored by Avistone Biotechnology Co., which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06307795 being conducted?
This trial has 10 study locations across California, Colorado, Florida, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced or Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of XB010 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.